ETORICOXIB: THERAPEUTIC POTENTIAL
https://doi.org/10.14412/2074-2711-2009-28
Abstract
The paper describes the therapeutic properties of nonsteroidal anti-inflammatory drugs (NSAID), among them there is etoricoxib, the most selective current COX-2 inhibitor that may be successfully used for both acute analgesia and the treatment of chronic pain in patients with dorsopathies. The important advantages of the drug are its easiness-to-use (once-daily dosing), a wide range of effective doses (from 30 to 120 mg/day), lower risk of gastrointestinal events, liver damage, and skin and respiratory reactions as compared with nonselective NSAIDs, which make etoricoxib an appropriate treatment option if relevant risk factors are present.
About the Author
A. E. Karateev
Research Institute of Rheumatology, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
References
1. <div><p>Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно, Д.Р. Штульмана. М., 2001;1.</p><p>Алексеев В.В., Подчуфарова Е.В., Яхно Н.Н. Алгоритмы диагностики и лечения пациентов с болевыми синдромами в пояснично-крестцовой области. Боль 2006;29-37.</p><p>Кукушкин М.Л. Значение местных анестетиков в комплексной терапии пациентов с болями в спине. Трудный пациент 2008;10(6):13-7.</p><p>European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006;15:192-300.</p><p>European guidelines for the management of acute nonspecific low back pain. Eur Spine J 2006;15:169-91.</p><p>Шостак Н.А. Дорсопатии - совершенствование терапевтических возможностей. Трудный пациент 2006;10:23-8.</p><p>Roelofs P. , Deyo R., Koes B. et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008;23(1):CD000396.</p><p>Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: Алмаз, 2006;88 с.</p><p>Matsumoto A., Cavanaugh P. Etoricoxib. Drugs Today (Barc) 2004;40(5):395-414.</p><p>Patrignani P. , Capone M., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin Pharmacother 2003;4(2):265-84.</p><p>Martina S., Vesta K., Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005;39(5):854-62.</p><p>Brooks P. , Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag 2006;2(1):45-57.</p><p>Schwartz J., Dallob A., Larson P. et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008;48(6):745-54.</p><p>White P. Multimodal analgesia: its role in preventing postoperative pain. Curr Opin Investig Drugs 2008;9(1):76-82.</p><p>Ochroch E., Mardini I., Gottschalk A. What is the role of NSAIDs in pre-emptive analgesia? Drugs 2003;63(24):2709-23.</p><p>Stephens J., Pashos C., Haider S. et al. Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors. Pharmacotherapy 2004;24(12):1714-31.</p><p>Rasmussen G., Malmstrom K., Bourne M. et al. Etoricoxib provides analgesic efficacy to patients after knee or hip replacement surgery: a randomized, double-blind, placebo-controlled study. Anesth Analg 2005;101(4):1104-11.</p><p>Puura A., Puolakka P. , Rorarius M. et al. Etoricoxib pre-medication for post-operative pain after laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2006;50(6):688-93.</p><p>Liu W., Loo C., Tan H. et al. Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26(6):666-70.</p><p>Manyou B., Phupong V. Prospective randomized, double-blinded, placebo-controlled trial of preoperative etoricoxib for pain relief in uterine fractional curettage under paracervical block. Eur J Obstet Gynecol Reprod Biol 2008;140(1):90-4.</p><p>Tanprasertkul C., Pongrojpow D. Efficacy of etoricoxib for pain relief during endometrial biopsy; a double blind randomized controlled trial. J Med Assoc Thai 2008;91(1):13-8.</p><p>Smirnov G., Terдvд M., Tuomilehto H. et al. Etoricoxib for pain management during thyroid surgery-a prospective, placebo-controlled study Otolaryngol Head Neck Surg 2008;138(1):92-7.</p><p>Siddiqui A., Sadat-Ali M., Al-Ghamdi A. et al. The effect of etoricoxib premedication on postoperative analgesia requirement in orthopedic and trauma patients. Saudi Med J 2008;29(7):966-70.</p><p>Malmstrom K., Sapre A., Couglin H. et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther 2004 May;26(5):667-79.</p><p>Chang D., Desjardins P. , King T. et al. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial. Anesth Analg 2004 Sep;99(3):807-15.</p><p>Clarke R., Derry S., Moore R. et al. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009;15(2):CD004309.</p><p>Schumacher H., Boice J., Dahikh D. et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.</p><p>Bingham C. 3rd, Sebba A., Rubin B. et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46(3):496-507.</p><p>Moore R., Derry S., McQuay H. Discontinuation rates in clinical trials in muscu-loskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther 2008;10(3):R53.</p><p>van der Heijde D., Baraf H., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52(4):1205-15.</p><p>Birbara C., Puopolo A., Munoz D. et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability-a randomized, placebo-controlled, 3-month trial. J Pain 2003;4(6):307-15.</p><p>Pallay R., Seger W., Adler J. et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66.</p><p>Zerbini C., Ozturk Z., Grifka J. et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin 2005;21(12):2037-49.</p><p>Ramey D., Watson D., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21(5):715-22.</p><p>Hunt R., Harper S., Callegari P. et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.</p><p>Watson D., Bolognese J., Yu C. et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004;20(12):1899-908.</p><p>Curtis S., Ko A., Bolognese J. et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Сurr Med Res Opin 2006;22(12):2365-74.</p><p>Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;18;368(9549):1771-81.</p><p>Quercia O., Emiliani F. , Foschi F. et al. Safety of etoricoxib in patients with reactions to NSAIDs. J Investig Allergol Clin Immunol 2008;18(3):163-7.</p><p>Viola M., Quaratino D., Gaeta F. et al. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2007;143(2):103-8.</p><p>El Miedany Y. , Youssef S., Ahmed I. et al. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97(1):105-9.</p></div><br />
Review
For citations:
Karateev AE. ETORICOXIB: THERAPEUTIC POTENTIAL. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;1(1):67-73. (In Russ.) https://doi.org/10.14412/2074-2711-2009-28
Views:
915
Email this article 